Skip to main content

Product Value — GORE® VIATORR® TIPS Endoprosthesis with Controlled Expansion

Provides clinical and economic value for treating patients with refractory ascites and variceal bleeding

Image of GORE® VIATORR® TIPS Endoprosthesis with Controlled ExpansionGORE® VIATORR® Device maintains significantly increased patency compared to bare metal stent alternatives. It is effective in lowering portal pressure gradients in patients with refractory ascites and variceal bleeding.* 

Clinical and economic value for treating patients with ascites 

TIPS with GORE® VIATORR® Device improves transplant-free survival and control of ascites compared to repeat paracentesis procedures.

Chart showing improved transplant-free survival and control of ascites compared to repeat paracentesis procedures

Clinical and economic value for patients with variceal bleeding

TIPS with GORE® VIATORR® Device improves survival and control of bleeding compared to repeat endoscopic procedures with medical management.

Chart showing improved survival and control of bleeding compared to repeat endoscopic procedures with medical management

Three people discussing documents

Connect with one of our Corporate Account Directors to learn more about the value Gore can deliver to your healthcare institution.

 

Contact us >

The Future of Value Analysis

A Handbook for Health Care Professionals

Read perspectives from value analysis professionals who share their thoughts regarding the importance of effective collaboration, paradigm shifts with determining value, and the critical focus on the future of healthcare.

 

Download the handbook >

To learn more, contact us.

INTENDED USE/INDICATIONS FOR USE: The GORE® VIATORR® TIPS Endoprosthesis is indicated for use in the de novo and revision treatment of portal hypertension and its complications such as variceal bleeding, gastropathy, refractory ascites and/or hepatic hydrothorax.  

CONTRAINDICATIONS: There are no known contraindications for this device.

Refer to Instructions for Use at eifu.goremedical.com for a complete description of all applicable indications, warnings, precautions and contraindications for the markets where this product is available. RXOnly

eIFU Symbol

* Data on file with Gore PMA P040027.

  1. Bureau C, Thabut D, Oberti D, et al. Transjugular intrahepatic portosystemic shunts with covered stents increase transplant-free survival of patients with cirrhosis and recurrent ascites. Gastroenterology 2017;152(1):157-163.
    http://www.sciencedirect.com/science/article/pii/S0016508516351101.
  2. Premier Applied Sciences®, Premier, Inc. Premier Healthcare Database: Data that Informs and Performs. Charlotte, NC: Premier, Inc; 2018. [White paper].
    https://learn.premierinc.com/white-papers/premier-healthcare-database-whitepaper.
  3. García-Pagán JC, Caca K, Bureau K, et al; Early TIPS (Transjugular Intrahepatic Portosystemic Shunt) Cooperative Study Group. Early use of TIPS in patients with cirrhosis and variceal bleeding. New England Journal of Medicine 2010;362(25):2370-2379. https://www.nejm.org/doi/full/10.1056/NEJMoa0910102.

21365820-EN